BeiGene (BGNE)
(Delayed Data from NSDQ)
$153.58 USD
+5.02 (3.38%)
Updated Apr 26, 2024 04:00 PM ET
Pre-Market: $156.79 +3.21 (2.09%) 8:40 AM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BGNE 153.58 +5.02(3.38%)
Will BGNE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BGNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BGNE
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
BGNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top 5 Momentum Picks for January After a Fabulous 2023
New Strong Buy Stocks for December 22nd
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
Other News for BGNE
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27)
AstraZeneca: Strong In A Weak Market
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)